Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
Lancet Glob Health. 2021 Mar;9(3):e257-e266. doi: 10.1016/S2214-109X(20)30544-1. Epub 2021 Jan 27.
The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May-June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34-1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India.
We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3-5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys.
Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8-7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2-8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26-32 infections for every reported COVID-19 case.
Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country.
Indian Council of Medical Research.
2020 年 5 月至 6 月,印度首次对全国范围内年龄在 18 岁及以上的成年人进行了严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)血清学调查,在 21 个邦的 700 个村庄或病房中发现 SARS-CoV-2 IgG 抗体血清阳性率为 0.73%(95%CI 0.34-1.13)。我们旨在评估印度目前全国范围内一般人群的血清阳性率。
我们在第一次血清学调查中包含的印度 70 个区的 700 个村庄或病房中,对年龄在 10 岁及以上的个体进行了第二次家庭血清学调查。年龄小于 10 岁的个体和未在调查时作出回应的家庭被排除在外。对参与者进行了访谈,以收集社会人口统计学、COVID-19 症状、与实验室确诊 COVID-19 病例的接触史以及 COVID-19 疾病史等信息。从每个参与者采集 3-5mL 的静脉血,并使用 Abbott SARS-CoV-2 IgG 检测试剂盒进行血液样本检测。应用抽样权重并调整聚类和检测特性后,对血清阳性率进行了估计。我们从每个家庭中随机选择了一个成人血清样本,比较了两次血清学调查中成年人群的血清阳性率。
2020 年 8 月 18 日至 9 月 20 日,我们从 15613 户家庭的 29082 名个体中招募并收集了血清样本。10 岁及以上个体 SARS-CoV-2 IgG 抗体的加权和调整血清阳性率为 6.6%(95%CI 5.8-7.4)。在随机选择的 15084 名成年人(每户一人)中,加权和调整后的血清阳性率为 7.1%(6.2-8.2)。血清阳性率在不同年龄组、性别和职业中相似。血清阳性率在城市贫民窟地区最高,其次是城市非贫民窟地区和农村地区。我们估计到 2020 年 8 月 18 日,该国累计有 7430 万例感染,每报告 1 例 COVID-19 病例就有 26-32 例感染。
到 2020 年 8 月 18 日,印度约有 15 分之一的 10 岁及以上个体感染了 SARS-CoV-2。2020 年 5 月至 8 月期间,成年人的血清阳性率增加了约十倍。8 月的感染与病例比低于 5 月,这反映了全国范围内检测量的大幅增加。
印度医学研究理事会。